The boom of copyright’s drug initially drove significant expansion in the pharmaceutical sector, creating a understanding of guaranteed gains. However, funding in companies solely reliant on blockbuster drugs like the erectile dysfunction pill presents substantial risks. Intellectual property expiration has led generic rivalry, decreasing revenue

The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for blockbuster treatments and impressive returns is certain, the linked risks are also significant. Man